Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 138
Filtrar
1.
Cancer Res Commun ; 4(4): 1024-1040, 2024 Apr 09.
Artículo en Inglés | MEDLINE | ID: mdl-38592451

RESUMEN

Non-Hodgkin lymphoma (NHL) is a common cancer in both men and women and represents a significant cancer burden worldwide. Primary effusion lymphoma (PEL) is a subtype of NHL infected with Kaposi sarcoma-associated herpesvirus (KSHV). PEL is an aggressive and lethal cancer with no current standard of care, owing largely to its propensity to develop resistance to current chemotherapeutic regimens. Here, we report a reliance of KSHV-positive PEL on the mitotic kinase, NEK2, for survival. Inhibition of NEK2 with the inhibitor, JH295, resulted in caspase 3-mediated apoptotic cell death of PEL. Furthermore, NEK2 inhibition significantly prolonged survival and reduced tumor burden in a PEL mouse model. We also demonstrate that the ABC transporter proteins, MDR1 and MRP, are most active in PEL and that inhibition of NEK2 in PEL reduced the expression and activity of these ABC transporter proteins, which are known to mediate drug resistance in cancer. Finally, we report that JH295 treatment sensitized lymphomas to other chemotherapeutic agents such as rapamycin, resulting in enhanced cancer cell death. Overall, these data offer important insight into the mechanisms underlying PEL survival and drug resistance, and suggest that NEK2 is a viable therapeutic target for PEL. SIGNIFICANCE: The mitotic kinase, NEK2, is important for the survival of KSHV-positive PEL. NEK2 inhibition resulted in PEL apoptosis and reduced tumor burden in a mouse model. NEK2 inhibition also reduced drug resistance.


Asunto(s)
Herpesvirus Humano 8 , Linfoma no Hodgkin , Linfoma de Efusión Primaria , Masculino , Animales , Ratones , Humanos , Femenino , Linfoma de Efusión Primaria/tratamiento farmacológico , Transportadoras de Casetes de Unión a ATP , Agresión , Modelos Animales de Enfermedad , Quinasas Relacionadas con NIMA/genética
3.
Anticancer Res ; 43(6): 2455-2465, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37247906

RESUMEN

BACKGROUND/AIM: Primary effusion lymphoma (PEL) is classified as a rare non-Hodgkin's B-cell lymphoma that is caused by Kaposi's sarcoma-associated herpesvirus (KSHV); PEL cells are latently infected with KSHV. PEL is frequently resistant to conventional chemotherapies. Therefore, the development of novel therapeutic agents is urgently required. Nigericin, a H+ and K+ ionophore, possesses unique pharmacological effects. However, the effects of nigericin on PEL cells remain unknown. MATERIALS AND METHODS: We examined the cytotoxic effects of the K+ ionophores, nigericin, nonactin, and valinomycin, on various B-lymphoma cells including PEL. We also evaluated ionophore-induced changes in signaling pathways involved in KSHV-induced oncogenesis. Moreover, the effects of nigericin on mitochondrial membrane potential and viral reactivation in PEL were analyzed. RESULTS: Although the three tested ionophores inhibited the proliferation of several B-lymphoma cell lines, nigericin inhibited the proliferation of PEL cells compared to KSHV-negative cells. In PEL cells, nigericin disrupted the mitochondrial membrane potential and caused the release of cytochrome c, which triggered caspase-9-mediated apoptosis. Nigericin also induced both an increase in phosphorylated p38 MAPK and proteasomal degradation of ß-catenin. Combination treatment of nigericin with the p38 MAPK inhibitor SB203580 potentiated the cytotoxic effects towards PEL cells, compared to either compound alone. Meanwhile, nigericin did not influence viral replication in PEL cells. CONCLUSION: Nigericin induces apoptosis in PEL cells by mitochondrial dysfunction and down-regulation of Wnt/ß-catenin signaling. Thus, nigericin is a novel drug candidate for treating PEL without the risk of de novo KSHV infection.


Asunto(s)
Antineoplásicos , Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/patología , Nigericina/metabolismo , Nigericina/farmacología , Nigericina/uso terapéutico , beta Catenina/metabolismo , Membranas Mitocondriales/metabolismo , Membranas Mitocondriales/patología , Línea Celular Tumoral , Apoptosis , Antineoplásicos/farmacología , Herpesvirus Humano 8/fisiología , Mitocondrias , Ionóforos/metabolismo , Ionóforos/farmacología , Ionóforos/uso terapéutico , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
4.
Pathobiology ; 90(5): 356-364, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36996787

RESUMEN

INTRODUCTION: Primary effusion lymphoma (PEL) is a malignant lymphomatous effusion, which by definition is Kaposi sarcoma herpesvirus/human herpesvirus 8-positive. PEL typically occurs in HIV-infected patients but can also occur in HIV-negative individuals, including in organ transplant recipients. Tyrosine kinase inhibitors (TKIs) are currently the standard of care for patients with chronic myeloid leukemia (CML), BCR::ABL1-positive. Although TKIs are extremely effective in treating CML, they alter T-cell function by inhibiting peripheral T-cell migration and altering T-cell trafficking and have been associated with the development of pleural effusions. CASE PRESENTATION: We report a case of PEL in a young, relatively immunocompetent patient with no history of organ transplant receiving dasatinib for CML, BCR::ABL1-positive. DISCUSSION: We hypothesize that the loss of T-cell function secondary to TKI therapy (dasatinib) may have resulted in the unchecked cellular proliferation of Kaposi sarcoma herpesvirus (KSHV)-infected cells, leading to the emergence of a PEL. We recommend cytologic investigation and KSHV testing in patients being treated with dasatinib for CML who present with persistent or recurrent effusions.


Asunto(s)
Infecciones por VIH , Herpesvirus Humano 8 , Leucemia Mielógena Crónica BCR-ABL Positiva , Linfoma de Efusión Primaria , Sarcoma de Kaposi , Humanos , Dasatinib/efectos adversos , Linfoma de Efusión Primaria/diagnóstico , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/inducido químicamente , Sarcoma de Kaposi/inducido químicamente , Leucemia Mielógena Crónica BCR-ABL Positiva/complicaciones , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/inducido químicamente , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico
5.
Int J Mol Sci ; 24(4)2023 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-36835344

RESUMEN

Primary effusion lymphoma (PEL) is a rare and aggressive B-cell lymphoma, against which current therapies usually fail. In the present study, we show that targeting HSPs, such as HSP27, HSP70 and HSP90, could be an efficient strategy to reduce PEL cell survival, as it induces strong DNA damage, which correlated with an impairment of DDR. Moreover, as HSP27, HSP70 and HSP90 cross talk with STAT3, their inhibition results in STAT3 de-phosphorylation and. On the other hand, the inhibition of STAT3 may downregulate these HSPs. These findings suggest that targeting HSPs has important implications in cancer therapy, as it can reduce the release of cytokines by PEL cells, which, besides affecting their own survival, could negatively influence anti-cancer immune response.


Asunto(s)
Daño del ADN , Proteínas de Choque Térmico HSP27 , Proteínas HSP70 de Choque Térmico , Proteínas HSP90 de Choque Térmico , Linfoma de Efusión Primaria , Terapia Molecular Dirigida , Humanos , Apoptosis , Línea Celular Tumoral , Citocinas , Proteínas de Choque Térmico HSP27/metabolismo , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas HSP90 de Choque Térmico/metabolismo , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/genética , Factor de Transcripción STAT3/metabolismo
7.
Int J Hematol ; 117(1): 137-142, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36066839

RESUMEN

Primary effusion lymphoma-like lymphoma (PEL-LL) shows a unique clinical presentation, characterized by lymphomatous effusions in the body cavities. PEL-LL may be associated with hepatitis C virus infections and fluid overload states; and owing to its rarity, no standard therapies have been established. We report a case of a 55-year-old woman who developed PEL-LL during treatment with dasatinib, for chronic myeloid leukemia (CML). She presented to our hospital with dyspnea lasting for approximately a month and showed pericardial and bilateral pleural effusions. The pericardial effusion was exudative, and cytopathological and immunophenotypic examinations showed numerous CD 20-positive, large atypical lymphoid cells, which were also positive for the Epstein-Barr virus gene. No evidence of lymphadenopathy or bone marrow infiltration was found. We diagnosed PEL-LL, immediately discontinued dasatinib, and performed continuous drainage of the pericardial effusions. Complete response was achieved, and remission was maintained for 15 months. Two months after discontinuation of dasatinib, she was administered imatinib and a deep molecular response for the CML was maintained. PEL-LL occurring during dasatinib treatment is rare. We compared the results of previous reports with this case, and found that early diagnosis of PEL-LL, discontinuation of dasatinib, and sufficient drainage can improve the prognosis of PEL-LL.


Asunto(s)
Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Linfoma , Derrame Pleural , Femenino , Humanos , Persona de Mediana Edad , Dasatinib/efectos adversos , Linfoma de Efusión Primaria/diagnóstico , Linfoma de Efusión Primaria/tratamiento farmacológico , Herpesvirus Humano 4 , Derrame Pleural/inducido químicamente
8.
Curr Opin Virol ; 56: 101270, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-36182745

RESUMEN

Kaposi's sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). Here, we review what is known about human gene essentiality in PEL-derived cell lines. We provide an updated list of PEL-specific human gene dependencies, based on the improved definition of core essential genes across human cancer types. The requirements of PEL cell lines for interferon regulatory factor 4 (IRF4), basic leukine zipper ATF-like transcription factor (BATF), G1/S cyclin D2 (CCND2), CASP8 and FADD like apoptosis regulator (CFLAR), MCL1 apoptosis regulator (MCL1), and murine double minute 2 (MDM2) have been confirmed experimentally. KSHV co-opts IRF4 and BATF to drive superenhancer (SE)-mediated expression of IRF4 itself, MYC, and CCND2. IRF4 dependency of SE-mediated gene expression is shared with Epstein-Barr virus-transformed lymphoblastoid cell lines (LCLs) and human T-cell leukemia virus type 1-transformed adult T-cell leukemia/lymphoma (ATLL) cell lines, as well as several B-cell lymphomas of nonviral etiology. LCLs and ATLL cell lines similarly share dependencies on CCND2 and CFLAR with PEL, but also have distinct gene dependencies. Genetic dependencies could be exploited for therapeutic intervention in PEL and other cancers.


Asunto(s)
Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 8 , Leucemia-Linfoma de Células T del Adulto , Linfoma de Efusión Primaria , Neoplasias , Adulto , Humanos , Animales , Ratones , Linfoma de Efusión Primaria/genética , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/metabolismo , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/metabolismo , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/uso terapéutico , Herpesvirus Humano 4/genética , Herpesvirus Humano 8/genética
9.
Int J Mol Sci ; 23(12)2022 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-35743211

RESUMEN

PEL is a rare B cell lymphoma associated with KSHV that mainly arises in immune-deficient individuals. The search for new drugs to treat this cancer is still ongoing given its aggressiveness and the poor response to chemotherapies. In this study, we found that DMF, a drug known for its anti-inflammatory properties which is registered for the treatment of psoriasis and relapsing-remitting MS, could be a promising therapeutic strategy against PEL. Indeed, although some mechanisms of resistance were induced, DMF activated NRF2, reduced ROS and inhibited the phosphorylation of STAT3 and the release of the pro-inflammatory and immune suppressive cytokines IL-6 and IL-10, which are known to sustain PEL survival. Interestingly, we observed that DMF displayed a stronger cytotoxic effect against fresh PEL cells in comparison to PEL cell lines, due to the activation of ERK1/2 and autophagy in the latter cells. This finding further encourages the possibility of using DMF for the treatment of PEL.


Asunto(s)
Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Apoptosis , Línea Celular Tumoral , Dimetilfumarato/farmacología , Dimetilfumarato/uso terapéutico , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Recurrencia Local de Neoplasia
10.
Leuk Res ; 116: 106826, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35316715

RESUMEN

Primary effusion lymphoma (PEL) is an aggressive B-cell non-Hodgkin lymphoma in immunocompromised individuals such as AIDS patients. PEL shows a poor prognosis (median survival time < 6 months) compared with other AIDS-related lymphomas, and is generally resistant to conventional treatments. Novel drugs for PEL treatment are required. Midkine inhibitor (iMDK) was previously found to suppress midkine protein expression. Interestingly, iMDK suppressed cell proliferation in PEL cell lines in a time- and dose-dependent manner, regardless of midkine gene expression. We examined the mechanism of iMDK on PEL. Importantly, iMDK strongly induced cell cycle arrest at the G2/M phase within 12 h of incubation and suppressed the p-CDK1 protein level, which is associated with the cell cycle checkpoint at G2/M, resulting in mitotic catastrophe with observation of multipolar division. After mitotic catastrophe, iMDK-treated PEL showed apoptosis with caspase-3, - 8, and - 9 activation at 24 h incubation. However, iMDK showed no effects on viral protein-activated signaling pathways such as JAK-STAT, PI3K-Akt and NF-κB, and HHV-8/KSHV gene expression in PEL. These results indicate that iMDK is a novel CDK1 inhibitor and a promising lead compound for PEL chemotherapy treatment.


Asunto(s)
Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Apoptosis , Puntos de Control de la Fase G2 del Ciclo Celular , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/metabolismo , Linfoma de Efusión Primaria/patología , Midkina/farmacología , Fosfatidilinositol 3-Quinasas/farmacología , Fosfatidilinositol 3-Quinasas/uso terapéutico
11.
BMJ Case Rep ; 15(3)2022 Mar 29.
Artículo en Inglés | MEDLINE | ID: mdl-35351773

RESUMEN

While infection should always lead the differential when a patient with AIDS presents with fever, inflammatory and malignant aetiologies should also be considered. With profound immunocompromise, malignancies can develop as sequelae of viral oncogene expression. Human herpesvirus 8 (HHV-8) infection drives several AIDS-related cancers including Kaposi sarcoma (KS), multicentric Castleman disease and primary effusion lymphoma (PEL), which can present simultaneously with variable clinical features. Herein, we describe a case of synchronous visceral KS and extracavitary PEL in a patient with AIDS. The patient was treated with systemic chemotherapy and remains in remission after four cycles. We review other cases of copresenting HHV-8-related malignancies, explore the salient pathomechanisms and clinical features of these cancers and discuss treatment strategies.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Enfermedad de Castleman , Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Sarcoma de Kaposi , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Humanos , Linfoma de Efusión Primaria/complicaciones , Linfoma de Efusión Primaria/diagnóstico , Linfoma de Efusión Primaria/tratamiento farmacológico , Sarcoma de Kaposi/tratamiento farmacológico
12.
Cancer Immunol Immunother ; 71(10): 2497-2509, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35262781

RESUMEN

Primary effusion lymphoma (PEL) is a rare aggressive B-cell non-Hodgkin's lymphoma with no optimal treatment. Signaling lymphocytic activation molecule-F7 (SLAMF7, CD319), a type I transmembrane glycoprotein highly expressed in multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. SLAMF7 also expresses on several hematopoietic lineages including NK cells. Elotuzumab (Elo), a humanized antibody targeting SLAMF7, is approved by FDA for MM treatment. In this study, we analyzed the expression of SLAMF7 on seven PEL cell lines. All PEL cells and NK cells showed high expression of SLAMF7. NK cells were enriched from PBMCs of healthy donors by MACS and expanded by co-culturing with MHC-class I negative K562 cells in the presence of IL-2 and IL-15. Expanded NK cells showed direct killing, and Elo demonstrated potent ADCC against PEL in an Effector:Target (E:T) dependent manner. Surface expression of CD107a on NK cells also increased in the process of ADCC. We also examined SLAMF7 expression of NK subpopulations and found that the CD56+CD16+ NK subpopulation demonstrated the highest SLAMF7 expression. Full-length-Elo but not F(ab')2-Elo exerts direct engagement to the expressing SLAMF7 on NK cells, promotes CD107a expression, and further augments NK cytotoxicity toward PEL. Elo enhanced survival of PEL-bearing immunodeficient mice with adoptive transfer of human NK cells. Taken together, our results show that NK cells play roles in PEL killing, and Elo causes ADCC/SLAMF7 ligation to boost NK cytotoxicity against PEL, offering promising preclinical evidence of Elo as a therapeutic monoclonal antibody treatment for PEL.


Asunto(s)
Antineoplásicos , Linfoma de Efusión Primaria , Mieloma Múltiple , Animales , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/farmacología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Citotoxicidad Celular Dependiente de Anticuerpos , Antineoplásicos/uso terapéutico , Humanos , Células Asesinas Naturales , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/metabolismo , Ratones , Mieloma Múltiple/tratamiento farmacológico
13.
Oncol Rep ; 47(3)2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-35014678

RESUMEN

Primary effusion lymphoma (PEL) is defined as a rare subtype of non­Hodgkin's B cell lymphoma, which is caused by Kaposi's sarcoma­associated herpesvirus (KSHV) in immunosuppressed patients. PEL is an aggressive type of lymphoma and is frequently resistant to conventional chemotherapeutics. Therefore, the discovery of novel drug candidates for the treatment of PEL is of utmost importance. In order to discover potential novel anti­tumor compounds against PEL, the authors previously developed a pyrrolidinium­type fullerene derivative, 1,1,1',1'­tetramethyl [60]fullerenodipyrrolidinium diiodide (derivative #1), which induced the apoptosis of PEL cells via caspase­9 activation. In the present study, the growth inhibitory effects of pyrrolidinium­type (derivatives #1 and #2), pyridinium­type (derivatives #3 and #5 to #9) and anilinium­type fullerene derivatives (derivative #4) against PEL cells were evaluated. This analysis revealed a pyridinium­type derivative (derivative #5; 3­â€‹5'­(etho xycarbonyl)­1',5'­dihydro­2'H­[5,6]fullereno­C60­Ih­[1,9­c]pyrrol­2'­yl]­1­methylpyridinium iodide), which exhibited antitumor activity against PEL cells via the downregulation of Wnt/ß­catenin signaling. Derivative #5 suppressed the viability of KSHV­infected PEL cells compared with KSHV­uninfected B­lymphoma cells. Furthermore, derivative #5 induced the destabilization of ß­catenin and suppressed ß­catenin­TCF4 transcriptional activity in PEL cells. It is known that the constitutive activation of Wnt/ß­catenin signaling is essential for the growth of KSHV­infected cells. The Wnt/ß­catenin activation in KSHV­infected cells is mediated by KSHV latency­associated nuclear antigen (LANA). The data demonstrated that derivative #5 increased ß­catenin phosphorylation, which resulted in ß­catenin polyubiquitination and subsequent degradation. Thus, derivative #5 overcame LANA­mediated ß­catenin stabilization. Furthermore, the administration of derivative #5 suppressed the development of PEL cells in the ascites of SCID mice with tumor xenografts derived from PEL cells. On the whole, these findings provide evidence that the pyridinium­type fullerene derivative #5 exhibits antitumor activity against PEL cells in vitro and in vivo. Thus, derivative #5 may be utilized as a novel therapeutic agent for the treatment of PEL.


Asunto(s)
Antineoplásicos/farmacología , Fulerenos/farmacología , Herpesvirus Humano 8/efectos de los fármacos , Linfoma de Efusión Primaria/tratamiento farmacológico , Vía de Señalización Wnt/efectos de los fármacos , beta Catenina/efectos de los fármacos , Animales , Línea Celular Tumoral , Modelos Animales de Enfermedad , Regulación hacia Abajo , Humanos , Ratones , Compuestos de Piridinio/farmacología
14.
Sci Rep ; 12(1): 1085, 2022 01 20.
Artículo en Inglés | MEDLINE | ID: mdl-35058488

RESUMEN

Overexpression of antiapoptotic BCL2 family proteins occurs in various hematologic malignancies and contributes to tumorigenesis by inhibiting the apoptotic machinery of the cells. Antagonizing BH3 mimetics provide an option for medication, with venetoclax as the first drug applied for chronic lymphocytic leukemia and for acute myeloid leukemia. To find additional hematologic entities with ectopic expression of BCL2 family members, we performed expression screening of cell lines applying the LL-100 panel. Anaplastic large cell lymphoma (ALCL) and primary effusion lymphoma (PEL), 2/22 entities covered by this panel, stood out by high expression of MCL1 and low expression of BCL2. The MCL1 inhibitor AZD-5991 induced apoptosis in cell lines from both malignancies, suggesting that this BH3 mimetic might be efficient as drug for these diseases. The ALCL cell lines also expressed BCLXL and BCL2A1, both contributing to survival of the cells. The combination of specific BH3 mimetics yielded synergistic effects, pointing to a novel strategy for the treatment of ALCL. The PI3K/mTOR inhibitor BEZ-235 could also efficiently be applied in combination with AZD-5991, offering an alternative to avoid thrombocytopenia which is associated with the use of BCLXL inhibitors.


Asunto(s)
Linfoma Anaplásico de Células Grandes/metabolismo , Linfoma de Efusión Primaria/metabolismo , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/metabolismo , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/metabolismo , Línea Celular Tumoral , Expresión Génica/genética , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Imidazoles/farmacología , Linfoma Anaplásico de Células Grandes/tratamiento farmacológico , Linfoma Anaplásico de Células Grandes/genética , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/genética , Compuestos Macrocíclicos/farmacología , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/antagonistas & inhibidores , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/genética , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Quinolinas/farmacología
15.
Cancer Immunol Immunother ; 71(5): 1017-1031, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-34545416

RESUMEN

Primary effusion lymphoma (PEL) is a rare, aggressive B cell non-Hodgkin's lymphoma of the body cavities with malignant effusions. The prognosis is poor, and no optimal treatment has been established. CD38 is a type II transmembrane glycoprotein known to overexpress in multiple myeloma (MM). Daratumumab (DARA), a human CD38-targeting monoclonal antibody (mAb), is approved for MM treatment. In this study, we found expression of CD38 on PEL cells and assessed the anti-PEL activity of DARA. We found that both KHYG-1 and N6 (CD16-transfected KHYG-1) NK cell lines showed direct killing activity against PEL cells with induction of CD107a, and NK-mediated cytotoxicity by N6NK (CD16+) cells increased with DARA treatment. We confirmed direct NK activity and antibody-dependent cell cytotoxicity (ADCC) by expanded NK cells, indicating that DARA has high ADCC activity. We elucidated the antibody-dependent cell phagocytosis (ADCP) by using human monocyte-derived macrophages (MDMs) and mouse peritoneal macrophages. DARA also showed potent complement-dependent cytolysis (CDC) toward PEL. DARA also induced PEL cell death in the presence of a cross-linking antibody. Moreover, treatment with DARA inhibited tumor growth in a PEL xenograft mouse model. These results provide preclinical evidence that Ab targeting of CD38 could be an effective therapeutic strategy for the treatment of PEL.


Asunto(s)
Antineoplásicos , Linfoma de Efusión Primaria , Mieloma Múltiple , ADP-Ribosil Ciclasa 1 , Animales , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Citotoxicidad Celular Dependiente de Anticuerpos , Antineoplásicos/uso terapéutico , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Ratones
16.
Rinsho Ketsueki ; 62(11): 1631-1634, 2021.
Artículo en Japonés | MEDLINE | ID: mdl-34866088

RESUMEN

Two cases of human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) involving unilateral pleural effusion that regressed only after drainage are reported. Cases 1 and 2 were 91- and 81-year-old men with right and left pleural effusion, respectively. No chemotherapy was administered to either patient because of their advanced age and the presence of cardiac comorbidities. They completely recovered after effusion drainage alone without relapse till the last observation. Thus, this study suggests that some patients with HHV8-negative EBL can be safely managed with effusion drainage alone.


Asunto(s)
Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Linfoma , Derrame Pleural , Drenaje , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Masculino , Recurrencia Local de Neoplasia , Derrame Pleural/terapia
17.
Rev Fac Cien Med Univ Nac Cordoba ; 78(4): 391-394, 2021 12 28.
Artículo en Español | MEDLINE | ID: mdl-34962734

RESUMEN

Introduction: Primary effusion lymphoma is a low-frequency and high-grade non-Hodgkin lymphoma caused by the Human Herpes virus 8. It mainly affects individuals infected with the human immunodeficiency virus (HIV), although it has also been described in HIV-negative cases. It is characterized by the presence of a malignant lymphomatous effusion in the different serous cavities, the pleural cavity being the most affected. Involvement outside the serosae is very rare. Diagnosis is made by analysis of the fluid accumulated in the serosae or by biopsy of the same, demonstrating the presence of characteristic neoplastic lymphocytes. Treatment consists of different chemotherapy regimens associated with antiretroviral therapy in HIV-positive patients. The prognosis of this disease is poor, with a survival of a few months after diagnosis. Methodology: We present the case of an 83-year-old man, HIV negative, with left pleural effusion and ascites, observing a fluid with a predominance of mononuclear cells without the presence of malignant cells on cytological examination. Results: The patient died and the autopsy made the diagnosis of Primary effusion lymphoma, also observing multisystemic extracavitary involvement. Conclusion: Although Primary effusion lymphoma preferentially affects HIV-positive individuals, the absence of HIV infection should not rule out the disease. Extracavitary involvement should be sought even in asymptomatic patients.


Introducción: El Linfoma primario de las efusiones es un Linfoma no Hodgkin de alto grado y escasa frecuencia producido por el virus Herpes Humano 8. Afecta principalmente a individuos infectados por el virus de la inmunodeficiencia humana (HIV), aunque también se ha descripto en HIV negativos. Se caracteriza por la presencia de derrame linfomatoso maligno en las distintas cavidades serosas siendo la cavidad pleural la más afectada. La afectación fuera de las serosas es muy poco frecuente. El diagnóstico se realiza por análisis del líquido acumulado en las serosas o mediante biopsia de las mismas demostrando la presencia de linfocitos neoplásicos característicos. El tratamiento consiste en distintos regímenes de quimioterapia asociados a terapia antirretroviral en pacientes HIV positivos. El pronóstico de esta enfermedad es pobre, con una supervivencia de escasos meses posteriores al diagnóstico. Metodología: Presentamos el caso de un varón de 83 años, HIV negativo, con derrame pleural izquierdo y ascitis, observándose un líquido con predominio de mononucleares sin presencia de células malignas al examen citológico. Resultados: El paciente falleció y mediante la autopsia se llegó al diagnóstico de Linfoma primario de las efusiones, observándose además afectación extracavitaria multisistémica. Conclusión: Si bien el Linfoma primario de las efusiones afecta preferentemente a individuos HIV positivos, la ausencia de infección por HIV no debe descartar la enfermedad. El compromiso extracavitario debe ser buscado aún en pacientes asintomáticos.


Asunto(s)
Infecciones por VIH , Herpesvirus Humano 8 , Linfoma de Efusión Primaria , Derrame Pleural Maligno , Anciano de 80 o más Años , Autopsia , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Linfoma de Efusión Primaria/diagnóstico , Linfoma de Efusión Primaria/tratamiento farmacológico , Masculino
18.
Phytother Res ; 35(12): 7018-7026, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34779075

RESUMEN

Acanthoic acid (AA) is an active substance that is extracted from Croton oblongifolius Roxb., a traditional plant in Thailand. The antiinflammatory effect of AA on NF-κB pathway has been exclusively reported, however, its anticancer effect is still lacking. PEL is a B cell lymphoma that is mostly found in HIV patients. The prognosis and progression of PEL patients are terribly poor with a median survival time less than 6 months, so the new effective treatment is urgently needed. In this study, we found that AA effectively inhibited PEL cell proliferation with IC50s at 120-130 µM in well-representative cells, while the IC50s of AA in PBMC were higher (>200 µM). AA increased percentages of Annexin V/PI positive cells, whereas adding of caspase inhibitor (Q-VD-OPh) prevented AA-induced cell death. The antiapoptotic protein, c-FLIP, was downregulated by AA which leading to the activation of caspase-8 and -3. Combination of AA and TRAIL dramatically enhanced apoptotic cell death. In PEL xenograft model, AA at the dose of 250 mg/kg effectively inhibited PEL tumor growth without detectable toxicities assessed by mice weight and appearance.


Asunto(s)
Diterpenos , Infecciones por VIH , Linfoma de Efusión Primaria , Animales , Apoptosis , Línea Celular Tumoral , Humanos , Leucocitos Mononucleares , Linfoma de Efusión Primaria/tratamiento farmacológico , Ratones
19.
Viruses ; 13(9)2021 09 09.
Artículo en Inglés | MEDLINE | ID: mdl-34578378

RESUMEN

Kaposi-sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-8) is the causative agent of several malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD). Active KSHV replication has also been associated with a pathological condition called KSHV inflammatory cytokine syndrome (KICS), and KSHV may play a role in rare cases of post-transplant polyclonal lymphoproliferative disorders. Several commonly used herpesviral DNA polymerase inhibitors are active against KSHV in tissue culture. Unfortunately, they are not always efficacious against KSHV-induced diseases. To improve the outcome for the patients, new therapeutics need to be developed, including treatment strategies that target either viral proteins or cellular pathways involved in tumor growth and/or supporting the viral life cycle. In this review, we summarize the most commonly established treatments against KSHV-related diseases and review recent developments and promising new compounds that are currently under investigation or on the way to clinical use.


Asunto(s)
Infecciones por Herpesviridae/tratamiento farmacológico , Herpesvirus Humano 8/efectos de los fármacos , Sarcoma de Kaposi/tratamiento farmacológico , Replicación Viral/genética , Animales , Sistemas CRISPR-Cas , Enfermedad de Castleman/tratamiento farmacológico , Ensayos Clínicos como Asunto , ADN Polimerasa Dirigida por ADN , Exodesoxirribonucleasas/antagonistas & inhibidores , Regulación Viral de la Expresión Génica , Infecciones por Herpesviridae/clasificación , Herpesvirus Humano 8/genética , Humanos , Linfoma de Efusión Primaria/tratamiento farmacológico , Ratones , Sarcoma de Kaposi/virología , Proteínas Virales/antagonistas & inhibidores , Latencia del Virus/genética , Replicación Viral/efectos de los fármacos
20.
Bull Cancer ; 108(10): 953-962, 2021 Oct.
Artículo en Francés | MEDLINE | ID: mdl-34246454

RESUMEN

Lymphomas remain a leading cause of morbidity and mortality for HIV-positive patients. The most common lymphomas include diffuse large B-cell lymphoma, Burkitt lymphoma, primary effusion lymphoma, plasmablastic lymphoma and Hodgkin lymphoma. Appropriate approach is determined by lymphoma stage, performans status, comorbidities, histological subtype, status of the HIV disease and immunosuppression. Treatment outcomes have improved due to chemotherapy modalities and effective antiretroviral therapy. This review summarizes epidemiology, pathogenesis, pathology, and current treatment landscape in HIV associated lymphoma.


Asunto(s)
Infecciones por VIH/complicaciones , Linfoma Relacionado con SIDA/virología , Fármacos Anti-VIH/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Burkitt/tratamiento farmacológico , Linfoma de Burkitt/patología , Linfoma de Burkitt/virología , Enfermedad de Castleman/tratamiento farmacológico , Enfermedad de Castleman/patología , Enfermedad de Castleman/virología , Infecciones por VIH/tratamiento farmacológico , Seropositividad para VIH/complicaciones , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/patología , Enfermedad de Hodgkin/virología , Humanos , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Huésped Inmunocomprometido , Incidencia , Linfoma Relacionado con SIDA/tratamiento farmacológico , Linfoma Relacionado con SIDA/epidemiología , Linfoma Relacionado con SIDA/patología , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/virología , Linfoma de Efusión Primaria/tratamiento farmacológico , Linfoma de Efusión Primaria/patología , Linfoma de Efusión Primaria/virología , Linfoma Plasmablástico/tratamiento farmacológico , Linfoma Plasmablástico/patología , Linfoma Plasmablástico/virología , Pronóstico , Recurrencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA